Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERW316 as Single Agent or Combination Therapy in Advanced Solid Tumors
NCT07570966Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Jun 2026
- Primary completion
- Aug 2031
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of ERW316 in breast cancer, solid tumor and prostate cancer (PCa) (5 arms), sponsored by Novartis. Primary endpoints: Dose-Limiting Toxicities at 28 days, Adverse Events and Serious Adverse Events at 2 years and 2 more. Planned start Jun 2026; status: withdrawn.
02
Drugs
ERW316
03
Conditions
breast cancersolid tumorprostate cancer (PCa)
Beyond the preview
Go deeper on NCT07570966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07570966.